Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Chubb
Queensland Health
Baxter
Julphar
Daiichi Sankyo
AstraZeneca
Deloitte
Cipla

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,964,592

« Back to Dashboard

Which drugs does patent 7,964,592 protect, and when does it expire?

Patent 7,964,592 protects ZYKADIA and is included in one NDA.

This patent has seventy-five patent family members in thirty-five countries.
Summary for Patent: 7,964,592
Title:2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
Abstract: Novel pyrimidine derivatives of formula I ##STR00001## to process for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
Inventor(s): Garcia-Echeverria; Carlos (Basel, CH), Kanazawa; Takanori (Tsukuba, JP), Kawahara; Eiji (Tsukuba, JP), Masuya; Keiichi (Tsukuba, JP), Matsuura; Naoko (Tsukuba, JP), Miyake; Takahiro (Tsukuba, JP), Ohmori; Osamu (Tsukuba, JP), Umemura; Ichiro (Tsukuba, JP)
Assignee: Novartis AG (Basel, CH)
Application Number:10/549,250
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 7,964,592

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp ZYKADIA ceritinib CAPSULE;ORAL 205755-001 Apr 29, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,964,592

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0305929.2Mar 14, 2003
United Kingdom0319227.5Aug 15, 2003
United Kingdom0322370.8Sep 24, 2003
PCT Information
PCT FiledMarch 12, 2004PCT Application Number:PCT/EP2004/002616
PCT Publication Date:September 23, 2004PCT Publication Number: WO2004/080980

Non-Orange Book US Patents Family Members for Patent 7,964,592

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,893,074 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders ➤ Try a Free Trial
8,263,590 Pyrimidine derivatives ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,964,592

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 045458 ➤ Try a Free Trial
Austria 497495 ➤ Try a Free Trial
Austria 542801 ➤ Try a Free Trial
Australia 2004220338 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Queensland Health
Covington
McKesson
Teva
Express Scripts
Cerilliant
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.